Chinese Herbal Medicine for Osteosarcoma in the Mouse: A Systematic Review and Meta-Analysis.
10.1007/s11655-018-2565-6
- Author:
Jun-Li CHANG
1
;
Wen-Yi WANG
1
;
Yi-Mian LI
1
;
Shao-Pu HU
1
;
Min YAO
1
;
Xue-Jun CUI
1
;
Wen-Lan ZHI
1
;
Qi SHI
1
;
Yong-Jun WANG
1
;
Yan-Ping YANG
2
Author Information
1. Orthopedic Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
2. Orthopedic Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. yanpingyangks@163.com.
- Publication Type:Journal Article
- Keywords:
Chinese herbal medicine;
meta-analysis;
mouse;
osteosarcoma;
systematic review;
xenograft model
- MeSH:
Animals;
Drugs, Chinese Herbal;
therapeutic use;
Mice;
Osteosarcoma;
drug therapy;
Publication Bias;
Risk Factors;
Tumor Burden;
drug effects;
Xenograft Model Antitumor Assays
- From:
Chinese journal of integrative medicine
2019;25(5):370-377
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To summarize and critically assess the inhibitory effects of Chinese herbal medicine (CHM) on tumor volume and tumor weight for the treatment of osteosarcoma (OS) in mouse models.
METHODS:PubMed, Embase, Web of Science, China Knowledge Resource Integrated Database (CNKI), Wanfang Database, VIP Database, and Chinese BioMedical (CBM) were searched since their inception dates to March 10, 2016. Two reviewers independently selected the controlled studies estimating effects of CHM on mouse OS by administration in vivo. A pair-wise meta-analysis was performed. Twenty-five studies with adequate randomization were included in the systematic review.
RESULTS:CHM may significantly inhibit OS growth in mice, as assessed using the tumor weight [20 studies, n=443; 290 for CHM and 153 for the control: pooled mean difference (MD)=-2.90; 95% confidence interval (Cl): -3.50 to -2.31: P<0.01], tumor volume (16 studies, n=382; 257 for CHM and 125 for the control; pooled MD =-2.57; 95% Cl: -3.33 to -1.80; P<0.01) and tumor growth inhibition rate.
CONCLUSION:CHM could significantly inhibit the growth of OS in mouse models, which might be supportive for the design of preclinical and clinical trials in future.
